stockportfolio.pro
SpyGlass Pharma, Inc. (SGP)
Healthcare · Biotechnology · NasdaqGS
SpyGlass Pharma, Inc. revenue & earnings — last 3 fiscal years
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Gross profit | — | — | — |
| Net income | $-13.32M | $-29.16M | $-39.87M |
| Net margin | — | — | — |
Source: SpyGlass Pharma, Inc. SEC filings (10-K).
Explore 3 years of SpyGlass Pharma, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track SGP in your portfolio →
SpyGlass Pharma, Inc. financial history by metric
About SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was incorporated in 2019 and is based in Aliso Viejo, California.
SpyGlass Pharma, Inc. — frequently asked questions
What is SpyGlass Pharma, Inc.'s revenue?
SpyGlass Pharma, Inc. (SGP) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is SpyGlass Pharma, Inc. profitable?
No — SGP reported a net loss of $-39.87M in fiscal 2025.
What is SGP's P/E ratio?
SpyGlass Pharma, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does SpyGlass Pharma, Inc. have?
As of fiscal year 2025, SGP carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is SpyGlass Pharma, Inc.'s market cap?
SpyGlass Pharma, Inc. (SGP) has a market capitalization of about $606.48M, based on the latest data in our nightly-refreshed cache.
When does SpyGlass Pharma, Inc.'s fiscal year end?
SGP's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from SpyGlass Pharma, Inc.'s official SEC filings (10-K and 10-Q), covering 3 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.